http://stroke.ahajournals.org/content/46/8/2197.abstract?etoc
- Cinara Stein, MSc;
- Carolina Gassen Fritsch, Ft;
- Caroline Robinson, MSc;
- Graciele Sbruzzi, DSc;
- Rodrigo Della Méa Plentz, DSc
+ Author Affiliations
- Reprint requests to Rodrigo Della Méa Plentz, PT, ScD, Physical Therapy Department, UFCSPA, Sarmento Leite, 245, CEP: 90050–170, Porto Alegre, RS, Brazil. E-mail roplentz@yahoo.com.br or rodrigop@ufcspa.edu.br
Abstract
Background and Purpose—Neuromuscular
electric stimulation (NMES) has been used to reduce spasticity and
improve range of motion in patients with
stroke. However, contradictory results have
been reported by clinical trials. A systematic review of randomized
clinical trials
was conducted to assess the effect of
treatment with NMES with or without association to another therapy on
spastic muscles
after stroke compared with placebo or another
intervention.
Methods—We searched
the following electronic databases (from inception to February 2015):
Medline (PubMed), EMBASE, Cochrane Central
Register of Controlled Trials and
Physiotherapy Evidence Database (PEDro). Two independent reviewers
assessed the eligibility
of studies based on predefined inclusion
criteria (application of electric stimulation on the lower or upper
extremities,
regardless of NMES dosage, and comparison
with a control group which was not exposed to electric stimulation),
excluding studies
with <3 days of intervention. The primary
outcome extracted was spasticity, assessed by the Modified Ashworth
Scale, and the
secondary outcome extracted was range of
motion, assessed by Goniometer.
Results—Of the
total of 5066 titles, 29 randomized clinical trials were included with
940 subjects. NMES provided reductions in spasticity
(−0.30 [95% confidence interval, −0.58 to
−0.03], n=14 randomized clinical trials) and increase in range of motion
when compared
with control group (2.87 [95% confidence
interval, 1.18–4.56], n=13 randomized clinical trials) after stroke.
Conclusions—NMES
combined with other intervention modalities can be considered as a
treatment option that provides improvements in spasticity
and range of motion in patients after stroke.
Clinical Trial Registration Information—URL: http://www.crd.york.ac.uk/PROSPERO. Unique identifier: CRD42014008946.
No comments:
Post a Comment